Avails Medical

What Avails Medical does

Avails Medical is a privately held clinical diagnostics company founded in 2013 and headquartered in Menlo Park, California, that develops electronic biosensor-based systems for rapid antimicrobial susceptibility testing (AST). The company targets hospital clinical microbiology laboratories serving patients with bloodstream infections and sepsis, addressing the 24-96 hour turnaround times of conventional AST workflows that contribute to sepsis mortality (over 50 million diagnosed annually worldwide with ~20% mortality) and antimicrobial resistance through delayed targeted antibiotic therapy.

The company's FDA-cleared eQUANT™ System uses potentiometric sensing of oxidation-reduction potential (ORP) changes from pathogen metabolism to generate a standardized 0.5 McFarland equivalent suspension (eMcFarland) directly from positive blood cultures in approximately 70 minutes, eliminating the overnight subculture step and reducing routine AST turnaround times by up to 24 hours. The system is cleared for 89 drug-bug combinations for gram-negative bacteria and demonstrated 95.0% overall categorical agreement with gold-standard methods across 2,679 AST result pairs in multicenter evaluation. The pipeline eAST™ System is a multi-slot rapid AST platform designed to deliver susceptibility results directly from positive blood cultures in approximately 5 hours, enabling potential same-day reporting. The company holds six issued U.S. patents and registered trademarks for the eQUANT, eAST, eTUBE, eLID, and ePANEL product lines.

Avails employs an enterprise field sales model targeting large hospital systems and academic medical centers, with its first U.S. commercial agreement signed in August 2025 with the flagship hospital of a six-hospital academic medical center system. Revenue mechanics combine capital sales of the eQUANT instrument with recurring consumables revenue from proprietary eTUBE disposable cuvettes required for each test run. The company has built out a commercial leadership team in 2024 including a VP of Sales (formerly T2 Biosystems), VP of Marketing (formerly bioMérieux/BioFire), VP of Finance (formerly Guardant Health/Deepcell), and EVP of Commercialization (formerly Karius/GenePOC). To date the company has been primarily funded through non-dilutive CARB-X grants (~$9.6 million received, with potential total of up to $14.7 million upon milestones) and earlier seed-stage rounds totaling approximately $7.4 million.

Name

Avails Medical

Legal name

Avails Medical, Inc.

Website

https://availsmedical.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Avails Medical is a clinical diagnostics company developing electronic biosensor systems for rapid antimicrobial susceptibility testing. Its FDA-cleared eQUANT System and pipeline eAST System serve hospital clinical microbiology laboratories, accelerating AST results from positive blood cultures.

Ownership category

akta.pro rank

Product category

Clinical Microbiology / Rapid Antimicrobial Susceptibility Testing (AST) Diagnostics

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)

akta.pro secondary industries

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations) (HLAGAIAD)

Keywords

• Rapid AST diagnostics
• Antimicrobial susceptibility testing
• Electronic biosensor technology
• Clinical microbiology instruments
• Blood culture diagnostics

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. eQUANT System Hardware Sales: Sale of the eQUANT instrument and consumables (eTUBE Disposables, workflow trays). The company signed its first commercial customer in August 2025, indicating early commercialization phase. System includes single module instrument with proprietary disposable components requiring ongoing purchase.
2. Consumables and Reagents: Ongoing revenue from proprietary consumables including eTUBE Disposables and reagent tubes required for each test run on the eQUANT System.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Avails Medical develops and sells the FDA-cleared eQUANT™ System, a bench-top instrument that uses proprietary electronic biosensor technology to generate a standardized 0.5 McFarland equivalent bacterial suspension directly from positive blood cultures in approximately 70 minutes, accelerating downstream disk diffusion antimicrobial susceptibility testing (AST) by up to 24 hours for hospital clinical microbiology laboratories. The company is also developing the eAST™ rapid AST system (multi-slot, ~5-hour results) and sells proprietary eTUBE disposable consumables used with the eQUANT System.

Product overview

Avails Medical offers a platform of rapid antibiotic susceptibility testing (AST) diagnostic products. The flagship FDA-cleared eQUANT™ System is an automated bench-top instrument that generates standardized bacterial inoculum (eMcFarland) directly from positive blood cultures for downstream disk diffusion AST, accelerating results by up to 24 hours. The eAST™ System (under development) is a next-generation multi-slot rapid AST platform designed to deliver same-day susceptibility results directly from positive blood cultures in approximately five hours. Both products leverage the company's proprietary electronic biosensor technology that detects real-time oxidation-reduction potential changes from pathogen metabolism, eliminating traditional manual culturing steps. The products are designed for clinical microbiology laboratories serving hospitals of all sizes.

Differentiator

Problem solved

Functional benefit

Brands

• eQUANT: FDA-cleared system that generates a 0.5 McFarland equivalent directly from positive blood cultures in approximately 70 minutes, enabling AST results up to 24 hours faster.
• eAST
• eTUBE

Products and services

• eQUANT™ System FDA-cleared automated bench-top instrument that uses potentiometric sensing of oxidation-reduction potential (ORP) changes from pathogen metabolism to generate a standardized 0.5 McFarland equivalent suspension (eMcFarland) directly from positive blood cultures in approximately 70 minutes, for use in downstream disk diffusion antimicrobial susceptibility testing (AST) by hospital clinical microbiology laboratories.
• eAST™ System Multi-slot rapid antibiotic susceptibility testing (AST) platform under development designed to deliver AST results directly from positive blood cultures in approximately five hours, using the company's electronic biosensor technology to measure real-time redox changes from pathogen metabolism for same-day susceptibility reporting in clinical microbiology laboratories.
• eTUBE™ Cuvette Proprietary disposable reagent tube (cuvette) used with the eQUANT System as part of its consumables workflow, enabling standardized bacterial suspension preparation for downstream disk diffusion AST. Sold as a recurring-use consumable to eQUANT System customers.

Quantifiable outcome

• Reduces AST turnaround time by up to 24 hours for gram-negative organisms from positive blood cultures
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• T2 Biosystems: T2 Biosystems develops rapid diagnostics for sepsis and bloodstream infections, including the T2Bacteria and T2Candida panels plus T2Resistance — directly comparable to Avails' mission of accelerating AST directly from positive blood cultures and competing for the same hospital microbiology budget.
• Accelerate Diagnostics: Accelerate Diagnostics offers the Accelerate Pheno system, which delivers rapid identification and AST directly from positive blood cultures in hours — the closest direct competitor to Avails' eAST product and targeting the same sepsis/AST clinical workflow.

Broad incumbents

• bioMérieux: bioMérieux is the dominant incumbent in clinical microbiology with the VITEK 2 AST system and BioFire bloodstream infection panels, serving as the entrenched competitor Avails must displace in hospital microbiology labs.
• Beckman Coulter (Danaher): Beckman Coulter's MicroScan system is one of the most widely deployed AST platforms in U.S. hospital microbiology labs, representing both a benchmark incumbent and a potential channel/integration partner for Avails' automation.
• Becton Dickinson (BD): BD's Phoenix M50 AST system and BD MAX molecular platform are entrenched in hospital microbiology workflows, making BD a key incumbent competitor and a likely strategic acquirer for differentiated rapid-AST technologies.

Emerging players

• Selux Diagnostics: Selux Diagnostics is developing rapid phenotypic AST platforms targeting the same bloodstream infection workflow as Avails' eAST, making it a comparable emerging competitor in the next-generation rapid-AST category.
• Qvella: Qvella is developing rapid sample-to-result diagnostics for bloodstream infections, with technology aimed at collapsing the time from positive blood culture to actionable ID/AST — overlapping with Avails' sepsis-focused workflow thesis.

Others

• Copan Diagnostics: Copan Diagnostics specializes in automated specimen processing and liquid-handling microbiology platforms (e.g., WASP), making it an adjacent player in laboratory sample-prep automation relevant to Avails' eQUANT/eTUBE consumables model.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/intent/tweet?text=
• LinkedInlinkedin.com/company/avails-medical-inc-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds7 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avails Medical